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SUMMARY – Diabetes is a major risk factor for cardiovascular disease. Despite recommendations 
and available therapeutic options, patients with diabetes do not always reach the recommended lipid 
levels. In this study, our aim was to compare the real world lipid profile of type 2 diabetes patients with 
guideline recommendations for dyslipidemia. Four hundred and sixty eight consecutive patients re-
ferred to Outpatient Diabetes Clinic of Istanbul Medeniyet University were recruited. Patient anthro-
pometric measurements (height, weight, waist circumference), biochemical test results (LDL choles-
terol (LDL-c), triglycerides, HDL cholesterol, HbA1c) and treatment modalities were recorded. Pa-
tients were stratified into cardiovascular risk categories according to the risk factors and their treatment 
dose was compared to the recommendations. Among 468 patients, 56 (12%) patients had coronary 
heart disease (CHD). Thirty-four percent of these patients were not on statin treatment (n=19) and 
their mean LDL-c level was 114±29 mg/dL (2.9±0.75 mmol/L). Nineteen percent of these patients 
were on high intensity statin treatment (atorvastatin 40-80 mg, rosuvastatin 20 mg). Only four patients 
with CHD had LDL-c levels <70 mg/dL (1.8 mmol/L). Four hundred and twelve patients had no 
CHD. In these patients, the mean LDL-c level was 132±38 mg/dL (3.4±0.9 mmol/L). Eighty (19%) 
patients had LDL-c level lower than 100 mg/dL (2.5 mmol/L). Overall 82% (n=384) of the cohort had 
not achieved treatment goal. In conclusion, a more pronounced approach for statin treatment is needed 
in diabetes patients for both primary and secondary prevention of cardiovascular diseases.
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Introduction
Cardiovascular diseases are the leading cause of 
death in the world1. Guidelines have been issued to 
decrease this rate and promote preventive cardiology2. 
Patients with atherosclerosis are at a higher risk com-
pared to normal population and lowering lipid levels is 
essential for populations at risk.
Diabetes is a major risk factor of cardiovascular 
disease3. It speeds atherosclerotic process and leads to 
ischemic heart disease. To lessen this atherosclerotic 
burden, the American Diabetes Association and Euro-
pean Society of Cardiology recommend LDL choles-
terol (LDL-c) levels to be lowered to less than 100 
mg/dL (2.5 mmol/L) in patients with diabetes4,5. 
Statins are available as lipid lowering drugs and their 
efficacy in diabetes is well studied6,7.
Despite recommendations and available therapeu-
tic options, patients with atherosclerotic heart disease 
do not always have low lipid levels. EUROASPIRE 
study has shown that almost half of the patients with 
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cardiovascular disease have higher LDL-c levels than 
recommended8.
In this study, our aim was to compare real world 
lipid profile of patients with type 2 diabetes with 
guideline recommendations for hyperlipidemia.
Material and Methods
The study was conducted at Outpatient Diabetes 
Clinic of Istanbul Medeniyet University. Ethical ap-
proval was obtained from the Istanbul Medeniyet 
University Ethics Committee.
Patients
Four hundred and sixty eight consecutive patients 
referred to Outpatient Diabetes Clinic were recruited. 
Patient anthropometric measurements (height, weight, 
waist circumference), biochemical test results (LDL-c, 
triglycerides, HDL cholesterol (HDL-c), HbA1c) and 
treatment modalities were recorded. Patients were 
stratified into cardiovascular risk categories according 
to the risk factors and their treatment dose was com-
pared to recommendations.
Anthropometric measures
Height was measured with a tape, weight with a 
digital scale, and waist circumference according to the 
NHANES III protocol by the same nurse8. After 
overnight fast, antecubital vein blood samples were 
collected into blood collection tubes including plain 
tubes without anticoagulant and tubes that contained 
EDTA. To obtain serum, the tubes were left to clot for 
1 hour at the most and then centrifuged at 1500 g for 
15 min. Serum samples were analyzed without delay. 
Whole blood samples for HbA1c were collected into 
blood tubes containing EDTA.
Serum glucose, transaminases, cholesterol (total 
cholesterol and HDL-c) and triglyceride levels were 
measured by an Architect c4000 analyzer (Abbott Lab-
oratories, IL, USA). HbA1c levels were analyzed using 
high performance liquid chromatography (Primus Ul-
tra2; Trinity Biotech USA Inc., NY, USA). LDL-c was 
estimated indirectly using Friedewald equation.
Statistical analysis
Statistical analyses were conducted with SPSS 21.0 
(IBM Corp., Armonk, NY, USA). The normality of 
distribution of variables was assessed with Shapiro-
Wilk and Kolmogorov-Smirnov tests. Subjects were 
compared for differences in two measurements using 
the paired samples t-test or Wilcoxon test. Correla-
tions between variables were determined by Pearson 
correlation test or Spearman’s rho. Data were expressed 
as mean ± standard deviation. The level of statistical 
significance was set at p<0.05 (two-tailed).
Results
Four hundred and sixty-eight patients (271 female 
and 197 male) were enrolled in the study. Their mean 
age was 58.1±10 years. Demographic characteristics of 
the patients are reported in Table 1.
The mean LDL-c level of the patients was 129±38 
mg/dL (3.3±0.9 mmol/L). The mean LDL-c level in 
patients without statin treatment was 134.7±37 mg/
dL (3.4±0.9 mmol/L). There were 20 (4%) patients 
with LDL-c <70 mg/dL (1.8 mmol/L) and 105 (22%) 
patients with LDL-c <100 mg/dL (2.5 mmol/L).
There were 56 (12%) patients with coronary heart 
disease (CHD). Thirty four percent of these patients 
were not on statin treatment (n=19) (Table 2) and 
their mean LDL-c level was 114±29 mg/dL (2.9±0.75 
mmol/L). Nineteen percent of these patients were on 
high intensity statin treatment (atorvastatin 40-80 mg, 
rosuvastatin 20 mg). Only four patients with CHD 
had LDL-c levels <70 mg/dL (1.8 mmol/L), which is 
the treatment goal for this patient population.
Four hundred and twelve patients had no CHD. 
Their mean LDL-c level was 132±38 mg/dL (3.4±0.9 
mmol/L) (Fig. 1). Sixty-seven patients were on statin 
treatment and 44% (n=30) had reached treatment goal. 
With or without treatment, 80 (19%) patients had 
LDL-c level lower than 100 mg/dL (2.5 mmol/L). 
Overall 82% (n=384) of the cohort had not achieved 
treatment goal.
There were 104 (22%) patients on statin treatment. 
Eight (7%) and 48 (44.4%) patients had LDL-c levels 
<70 mg/dL (1.8 mmol/L) and <100 mg/dL (2.5 
mmol/L), with the mean LDL levels of 65±2 mg/dL 
(1.6±0.005 mmol/L) and 80±10 mg/dL (2±0.2 
mmol/L), respectively. Overall, 65% of the patients on 
statin treatment had not reached treatment goal.
Among patients on statin treatment, 8% (n=9) used 
high intensity treatment, whereas 92% (n=99) were on 
moderate intensity treatment. Forty nine percent (n=53) 
M. Vural Keskinler et al. Real world lipid profile of patients with type 2 diabetes
Acta Clin Croat, Vol. 60, No. 1, 2021 65
of them were on atorvastatin 10 mg, 27% (n=29) on 
atorvastatin 20 mg, 5.5% (n=6) on atorvastatin 40 mg, 
14.8% (n=16) on rosuvastatin 10 mg, 0.9% (n=1) on ro-
suvastatin 20 mg, 0.9% (n=1) on rosuvastatin 40 mg, 
and 1.9% (n=2) on both fibrate and statin treatment 
(atorvastatin 40 mg, rosuvastatin 10 mg).
The mean triglyceride level in study patients was 
179±87 mg/dL (2.02±0.9 mmol/L). Fourteen patients 
were only on fibrate treatment. In these patients, the 
mean triglyceride level was 206±90 mg/dL (2.3±1 
mmol/L).
According to ADA guidelines, 80% (n=375) of the 
patients aged 40-75 should have received moderate-
intensive statin treatment; however, 82.4% (n=309) of 
this population had received no treatment. ADA also 
recommends moderate-intensive statin therapy in pa-
tients aged >75 (n=20). In our cohort, 95% (n=19) had 
received no treatment and 5% (n=1) were on moderate 
statin treatment.
The mean HbA1c percent in patients using statin 
therapy was 8.2%±2, whereas in those without statin 
therapy it was 8.8%±2, yielding a statistically signifi-
cant difference (p=0.01). There was no difference be-
tween the groups using statin and not using statin ac-
cording to waist circumference, LDL-c levels, BMI, 
total cholesterol, fasting serum glucose, and age.
Discussion
The results of our study showed that they were far 
from achieving treatment goals for hyperlipidemia in 
patients with diabetes. Study results revealed that pa-
tients with diabetes did not use statin treatment as 
 indicated, and patients with established CHD did not 
use statin for secondary prevention. The reasons for 
underachievement of treatment goals should be thor-
oughly examined.
Aside from the fact that patients with diabetes 
were not on recommended therapy for primary pre-
vention, a more disturbing finding was that patients 
with both CHD and diabetes were not on recom-
mended therapy. Ninety percent of CHD patients had 
not reached recommended LDL levels and 34% of 
them did not use statin at all. A worldwide analysis 
showed that statins were used in only 16.7% of pa-
tients for secondary prevention of CHD9. A large gap 
exists even between high-income countries and upper 
middle-income countries (70.9% vs. 20.1%). Also, 
Mansur et al. report on the financial burden of statins 
as one of the main causes of the lack of adherence10; 
however, in Turkey, drug costs are covered by the gov-
ernment, therefore, it is an unlikely cause for nonad-
herence in this cohort.
Table 2. Rate of statin use according to coronary heart 
disease (CHD)
Statin use With CHDn=56
Without CHD
n=412
Using statin 37 (66%) 67 (16%)
Not using statin 19 (34%) 345 (87%)
Table 1. Demographic characteristics of the cohort
Demographic characteristic Mean Standard deviation
Age (yrs) 58.1752 10.2
Height (cm) 163.1049 8.9
Weight (kg) 83.1413 13.8
Duration of diabetes (yrs) 8.4209 6.6
Glucose (g/dL) 188.1028 83.5
Creatinine (g/dL) 1.0205 3.4
Triglycerides (g/dL) 179.4528 87.2
High-density lipoprotein 
cholesterol (g/dL) 43.0325 10.8
Low-density lipoprotein 
cholesterol (g/dL) 129.6966 38.8
Alanine aminotransferase  
(g/dL) 26.6681 27.0
HbA1c (%) 8.7465 2.2
Body mass index (kg/m2) 31.4815 5.1
Total cholesterol (g/dL) 209.7539 48.3
Fig. 1. Number of patients on statin therapy.
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Patients sometimes abandon statin therapy due to 
side effects. Patients may have myalgia and rarely more 
serious effects can be observed, such as myopathy or 
rhabdomyolysis. In a meta-analysis with 46,262 sub-
jects by Finegold et al., side effects attributed to statin 
treatment were minor and most of them were also seen 
with placebo11. Guidelines advocate that there is no 
need for creatinine kinase follow up in patients started 
on statin therapy5. It is only indicated in patients with 
symptoms.
Polypharmacy is a major concern in patients with 
diabetes. Patients without glycemic control often use 
both oral and injectable drugs. A study by Grant et al. 
reports that the mean number of drugs used by diabetes 
patients is 412. Addition of another drug for prevention 
is not welcome by most of the patients. However, our 
analysis showed better glycemic control in patients on 
statin treatment. This finding may reflect the patient 
overall behavioral pattern related to his/her health care.
The AUDIT study has revealed that many physi-
cians do not acknowledge diabetes as a cardiovascular 
risk factor13. Another physician related issue is that the 
recommended dose of statin often is not prescribed. 
Heintjes et al. showed the goal achievement rates to 
decrease without optimal therapy, and it was also af-
fected by the statin therapy prescribed14. With pravas-
tatin and simvastatin, lesser decrease is seen in hyper-
lipidemia compared to atorvastatin and rosuvastatin. 
ADA recommendation for patients of all ages with 
diabetes and atherosclerotic cardiovascular disease is 
that high-intensity statin therapy should be added to 
lifestyle therapy. In our study, only 19% of the patients 
were on recommended therapy.
There are doctors who advocate against statin use 
in patients with clear indications for treatment and 
media organizations prefer to interview these doctors 
for more attraction. Although scientific societies clear-
ly explain the need for drug therapy in selected popu-
lations, these statements often are not heard enough. 
As a result, more and more people become reluctant to 
the initiation of statins and patient compliance de-
creases daily. Although nonadherence is a major prob-
lem for statin use, the use of other drugs such as hyper-
tension medication is not optimal either15. There are 
single pills to increase adherence to hypertension and 
hyperlipidemia drugs and they are well tolerated16.
Limitations of the study include observational na-
ture of the study. Also, patient history of statin use was 
not inquired, therefore we could not provide informa-
tion regarding the causes of not using statins.
In conclusion, our study showed that a more pro-
nounced approach for statin treatment is needed in 
patients with diabetes for both primary and secondary 
prevention of cardiovascular diseases. Along with pa-
tient education, physician centered educational courses 
are needed.
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Sažetak
USPOREDBA STVARNOG PROFILA LIPIDA  
U BOLESNIKA S DIJABETESOM TIP 2 I PREPORUKA IZ SMJERNICA
M. Vural Keskinler, I. Bozkurt, O. Telci Caklili, G. Feyizoglu, Z. Gul, A. Karsli i A. Oguz
Dijabetes je glavni čimbenik rizika za srčanožilne bolesti. Usprkos preporuka i dostupnih terapijskih mogućnosti bole-
snici s dijabetesom ne postižu uvijek preporučene razine lipida. Cilj ovoga istraživanja bio je usporediti stvarni profil lipida u 
bolesnika s dijabetesom tip 2 s preporukama za dislipidemiju iz dotičnih smjernica. U istraživanje je bilo uključeno 468 
uzastopnih bolesnika upućenih u Ambulantu za dijabetes Sveučilišta Medeniyet u Istanbulu. Bilježena su antropometrijska 
mjerenja (visina, težina, opseg struka), rezultati biokemijskih pretraga (LDL kolesterol, trigliceridi, HDL kolesterol, HbA1c) 
i načini liječenja. Bolesnici su podijeljeni u skupine kardiovaskularnog rizika prema rizičnim čimbenicima, a doze lijeka 
 kojom su liječeni uspoređene su s preporukama. Među 468 bolesnika 56 (12%) ih je imalo koronarnu srčanu bolest (KSB); 
34% (n=19) tih bolesnika nije primalo terapiju statinima, a njihova srednja razina LDL bila je 114±29 mg/dL (2,9±0,75 
mmol/L); 19% tih bolesnika primalo je visoko intenzivnu terapiju statinima (atorvastatin 40-80 mg, rosuvastatin 20 mg). 
Razine LDL <70 mg/dL (1,8 mmol/L) zabilježene su u samo četvero bolesnika s KSB. Četiristodvanaest bolesnika nije 
imalo KSB. U ovih bolesnika srednja razina LDL bila je 132±38 mg/dL (3,4±0,9 mmol/L). Razine LDL niže od 100 mg/
dL (2,5 mmol/L) zabilježene su u 80 (19%) bolesnika s LDL. Dakle, cilj liječenja sveukupno nije postignut u 82% (n=384) 
ispitivanih bolesnika. Zaključuje se kako je potreban snažniji pristup terapiji statinima u bolesnika s dijabetesom kako za 
primarnu tako i za sekundarnu prevenciju srčanožilnih bolesti.
Ključne riječi: Dijabetes tip 2; Dislipidemija; Koronarna srčana bolest
